Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Adverse reactions to patent blue V dye – The NEW START and ALMANAC experience

Barthelmes, Ludger, Goyal, Amit, Newcombe, Robert Gordon ORCID: https://orcid.org/0000-0003-4400-8867, McNeill, F. and Mansel, Robert Edward ORCID: https://orcid.org/0000-0002-8051-0726 2010. Adverse reactions to patent blue V dye – The NEW START and ALMANAC experience. European Journal of Surgical Oncology (EJSO) 36 (4) , pp. 399-403. 10.1016/j.ejso.2009.10.007

Full text not available from this repository.

Abstract

Background Blue dye with or without isotope has been widely used to identify the sentinel lymph node(s) in breast cancer. Patent blue V is used in the UK while its isomer isosulfan blue is used in the US. The allergic potential of isosulfan blue is well documented (1.4% adverse reactions) but that of patent blue V is less clearly defined. Methods In this paper we review the adverse reactions of patent blue V in 7,917 patients who participated in the NEW START training programme and the ALMANAC trial. All patients underwent sentinel lymph node biopsy for breast carcinoma using patent blue V in combination with 99mTc-albumin colloid. Results In total, 72 of 7,917 (0.9%) patients experienced adverse reactions : non-allergic reactions were observed in 4 (0.05%) patients, 23 (0.3%) patients had minor grade I allergic skin reactions (urticaria, blue hives, pruritis, or generalised rash) and 16 (0.2%) had grade II reactions (transient hypotension/bronchospasm/laryngospasm). Severe Grade III reactions (severe hypotension requiring vasopressor support and/or change/abandoning of planned procedure and/or HDU/ITU admission) were noted in 5 (0.06%) patients. The type of adverse reaction was not specified in 24 (0.3%) patients. No mortality was recorded. Conclusion The allergic potential of patent blue V dye compares favourably with isosulfan blue however both the surgeon and anaesthetist need to be alert to the risk of allergic reactions.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords: Allergy; Anaphylaxis; Breast cancer; Isosulfan blue; Patent blue V; Sentinel lymph node biopsy
Publisher: Elsevier
ISSN: 0748-7983
Last Modified: 19 Oct 2022 10:33
URI: https://orca.cardiff.ac.uk/id/eprint/24801

Citation Data

Cited 110 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item